Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05806554 · ClinicalTrials.gov registry record

Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial

A clinical trial of Diabetes Mellitus, sponsored by Sinocare.

Completed
Registry status
159
Enrollment target
6
Study locations

NCT05806554 is a study of Diabetes Mellitus that has completed, run by Sinocare. The registered enrollment target is 159 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05806554, a study of Diabetes Mellitus, has completed, sponsored by Sinocare.

COMPLETED
Registry status
159 participants
Enrollment target
6
Study locations

Study Summary

The purpose of the investigation is to evaluate the performance of the I3 CGM according to the FDA's special controls for iCGM.

Conditions Studied

Interventions

  • DEVICE Continuous glucose monitoring device

Study Locations (6)

Other

  • PSHI Praxis GmbH - Mainz
  • Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm - Ulm

Arkansas

  • Woodland Research Northwest - Rogers

California

  • Diablo Clinical Research - Walnut Creek

Georgia

  • Atlanta Diabetes Associates - Atlanta

Washington

  • Rainier Clinical Research Center - Renton

Trial Details

FieldValue
Enrollment Target 159 participants
Start Date 2023-07-19
Est. Completion 2024-10-22

Sponsor

Sinocare

2 total trials

What the Registry Record Tells You About NCT05806554

The ClinicalTrials.gov registry entry for NCT05806554 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (91% lower). The listed sponsor is Sinocare, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Continuous glucose monitoring device is the first listed.

NCT05806554 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT05806554 about?

NCT05806554 is a clinical study titled "Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial". The purpose of the investigation is to evaluate the performance of the I3 CGM according to the FDA's special controls for iCGM.

What is the current status of trial NCT05806554?

This trial is currently completed. The enrollment target is 159 participants. The study started on 2023-07-19. Estimated completion is 2024-10-22.

What conditions does trial NCT05806554 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT05806554?

The interventions under investigation include: Continuous glucose monitoring device (DEVICE).

Who is sponsoring clinical trial NCT05806554?

This trial is sponsored by Sinocare, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05806554 being conducted?

This trial has 6 study locations across Arkansas, California, Georgia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.